Article
The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
Molecular cancer research : MCR - 1 Aug 2020
Pierro Joanna, Saliba Jason, Narang Sonali, Sethia Gunjan, Saint Fleur-Lominy Shella, Chowdhury Ashfiyah, Qualls Anita, Fay Hannah, Kilberg Harrison L, Moriyama Takaya, Fuller Tori J, Teachey David T, Schmiegelow Kjeld, Yang Jun J, Loh Mignon L, Brown Patrick A, Zhang Jinghui, Ma Xiaotu, Tsirigos Aristotelis, Evensen Nikki A, Carroll William L
Abstract excerpt
The NSD2 p.E1099K (EK) mutation is observed in 10% of acute lymphoblastic leukemia (ALL) samples with enrichment at relapse indicating a role in clonal evolution and drug resistance. To discover mechanisms that mediate clonal expansion, we engineered B-precursor ALL (B-ALL) cell lines (Reh, 697) to overexpress wildtype (WT) and EK NSD2, but observed no differences in proliferation, clonal growth, or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.